Article

Validation of affinity reagents using antigen microarrays

Science for Life Laboratory Stockholm, School of Biotechnology, KTH - Royal Institute of Technology, Box 1031, SE-171 21 Solna, Sweden.
New Biotechnology (Impact Factor: 2.11). 11/2011; 29(5):555-63. DOI: 10.1016/j.nbt.2011.11.009
Source: PubMed

ABSTRACT There is a need for standardised validation of affinity reagents to determine their binding selectivity and specificity. This is of particular importance for systematic efforts that aim to cover the human proteome with different types of binding reagents. One such international program is the SH2-consortium, which was formed to generate a complete set of renewable affinity reagents to the SH2-domain containing human proteins. Here, we describe a microarray strategy to validate various affinity reagents, such as recombinant single-chain antibodies, mouse monoclonal antibodies and antigen-purified polyclonal antibodies using a highly multiplexed approach. An SH2-specific antigen microarray was designed and generated, containing more than 6000 spots displayed by 14 identical subarrays each with 406 antigens, where 105 of them represented SH2-domain containing proteins. Approximately 400 different affinity reagents of various types were analysed on these antigen microarrays carrying antigens of different types. The microarrays revealed not only very detailed specificity profiles for all the binders, but also showed that overlapping target sequences of spotted antigens were detected by off-target interactions. The presented study illustrates the feasibility of using antigen microarrays for integrative, high-throughput validation of various types of binders and antigens.

Download full-text

Full-text

Available from: Peter Nilsson, Oct 31, 2014
0 Followers
 · 
168 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Affinity proteomics is the field of proteome analysis based on the use of antibodies and other binding reagents as protein-specific detection probes. In this review, the particular strengths of affinity methods for determination of protein localization, functional characterization, biomarker discovery and intracellular applications, and their resulting impact in basic and clinical research are highlighted. An additional focus is on the requirements for systematic binder generation and current large-scale binder projects, including bioinformatic frameworks for epitope selection and for documentation of available binding reagents and their performance. In addition to current affinity proteomics methods and applications, including arrays of proteins, binders, lysates and tissues, approaches coupling mass spectrometry-based proteomics and affinity proteomics are reviewed.
    Expert Review of Proteomics 08/2012; 9(4):401-14. DOI:10.1586/epr.12.34 · 3.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The determination of the protein composition is a challenging task, yet a valuable endeavor. Information that lies within the composition can help predicting pathogenic mechanisms and diseases. Therefore, a mandatory requirement is the accurate quantification. Protein microarrays are a promising alternative to complement mass spectrometry (MS) techniques. Nevertheless, effects in microarray production and assay development may lead to altered signal intensities. Techniques like NormaCurve provide a more robust quantification by taking the immobilized protein content into account. Printing dilution series can be used to construct a non-linear standard curve to estimate the amount of bound IgG, which helps to overrule the detection range of one order of magnitude. Standard protocols based on projects like the 'minimum information about a proteomics experiment' will help to improve quality and overall comparability.
    Current opinion in chemical biology 11/2013; 18C:16-20. DOI:10.1016/j.cbpa.2013.10.024 · 7.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with well-differentiated small intestine neuroendocrine tumors (WD-SI-NETs) are most often diagnosed at a metastatic stage of disease, which reduces possibilities for a curative treatment. Thus new approaches for earlier detection and improved monitoring of the disease are required. Suspension bead arrays targeting 124 unique proteins with antibodies from the Human Protein Atlas were used to profile biotinylated serum samples. Discoveries from a cohort of 77 individuals were followed up in a cohort of 132 individuals both including healthy controls as well as patients with untreated primary WD-SI-NETs, lymph node metastases and liver metastases. A set of 20 antibodies suggested promising proteins for further verification based on technically verified statistical significance. Proceeding, we assessed the classification performance in an independent cohort of patient serum, achieving, classification accuracy of up to 85% with different subsets of antibodies in respective pairwise group comparisons. The protein profiles of nine targets, namely IGFBP2, IGF1, SHKBP1, ETS1, IL1α, STX2, MAML3, EGR3 and XIAP were verified as significant contributors to tumor classification. We propose new potential protein biomarker candidates for classifying WD-SI-NETs at different stage of disease. Further evaluation of these proteins in larger sample sets and with alternative approaches is needed in order to further improve our understanding of their functional relation to WD-SI-NETs and their eventual use in diagnostics.
    PLoS ONE 11/2013; 8(11):e81712. DOI:10.1371/journal.pone.0081712 · 3.53 Impact Factor